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B 4.3
Endovascular Procedures for Intermittent
Claudication
B 4.3.1
General Concepts Regarding Catheter Intervention in
PAD
Intervention by endovascular procedure or surgery is
only indicated in selected patients with IC in whom
exercise treatment has failed. Imaging-guided catheter
intervention for PAD was first described by Dotter
and Judkins! in 1964. Since that original report of PTA
in femoropopliteal arteries using coaxial catheter tech-
niques, more than 30 years have passed. The materials
and methods have now been refined, practitioners
have been and continue to be trained, and the applica-
tion of percutaneous transluminal balloon angioplasty
(PTA) and now stenting in PAD has become more
widespread.
Endovascular interventions other than balloon and
stcnt procedures may have a limited application in
selected patients and are therefore not emphasised
here. The following section considers the role of PTA
and stenting in PAD patients with IC and aortoiliac
disease, femoropopliteal disease, or both. Most trials
cited were on claudicants only. Thrombolytic therapy
has a role in some new claudicants and in previously
stable claudicants whose symptoms worsen because
of thrombosis superimposed on atherosclerotic steno-
sis (particularly those with thrombus-dominant rather
Treatment of Intermittent Claudication 883
than plaque-dominant occlusions). However, the topic
of thrombolytic therapy in PAD has been treated in
another consensus document and will be discussed in
Acute and Critical Limb Ischaemia (sections C and
D).2
Although the degree of disability is obviously a prime
consideration, anticipated short- and long-term clinical
benefit is the major determinant of the role of catheter
techniques in the management of claudication. Metallic
stents are surely the latest major technical/rnethodolog-
ical development to impact endovascular treatment of
PAD, and stented endografts may soon follow.
However, to appreciate their currently understood role
in the treatment of patients with Ie, it is first necessary
to know the indications and results of PTA above and
below the inguinal ligament and their relationship to
lesion characterisation. It is also necessary to appreciate
the problems and limitations of both the disease/treat-
ment and the evidence in the literature.
The issue of the preferred interventional technique for
particular types of lesions needs to be addressed.
However, it is difficult to be categorical about such rec-
ommendations, because the management of an individ-
ual lesion in a particular patient depends on a large
number of factors. Management will vary according to
local circumstances. Furthermore, with the rapid devel-
opment of new interventional techniques, the optimal
treatment for a particular patient will vary not only from
place to place but also within the same institution as
new expertise is developed. It has therefore been decid-
ed to define types of lesions for interventions and then
place them in four groups, each group usually being
treated in a similar way. The two extremes are type A
lesions, in which endovascular approach is the treat-
ment of choice, and type D lesions, in which surgery is
the treatment of choice. Between these two groups are
types Band C lesions, in which no firm recommenda-
tions can be made about the preferred interventional
option. At present, endovascular treatment is more com-
monly used in type B lesions, and surgical treatment is
more commonly used in type C lesions. It should be
emphasised that there is insufficient solid evidence to
make any firm recommendations, particularly in the
case of types Band C. This proposed classification of
types of lesions may have the advantage of encouraging
the standardisation of description of lesions and pro-
moting the reporting of results in such a way that in the
future it will be possible to make firmer recommenda-
tions about the optimal treatment for particular types of
lesion. This system of presentation is used throughout
the document to categorise types of lesions and their
preferred treatment. This system was devised in a simi-
lar structure to the AHA classification, but differs signif-
icantly in content.
84.3.2
Aortoiliac PTA
PTA is generally applied to more focal disease, for
instance, of the distal abdominal aorta, common iliac
arteries, and external iliac arteries. For diffuse, extensive,
complex, multilevel, multifocal, or totally occluded ath-
erosclerotic segments of the infrarenal abdominal aorta
and iliac arteries, the procedure of choice is surgery.
Recommendation 31: Morphological stratification
of iliac lesions
TASC type A iliac lesions:
1. Single stenosis <3 em of the CIA or EIA (unilat-
eral/bilateral)
TASC type B iliac lesions:
2. Single stenosis 3-10 em in length, not extending
into the common femoral artery (CFA)
3. Total of two stenosis <5 em long in the CIA
and/or EIA and not extending into the CFA
4. Unilateral CIA occlusion
TASC type C iliac lesions:
5. Bilateral 5-10-cm-Iong stenosis of the CIA
and/or EIA, not extending into the CFA
6. Unilateral EIA occlusion not extending into the
CFA
7. Unilateral EIA stenosis extending into the CFA
8. Bilateral CIA occlusion
TASC type D iliac lesions:
9. Diffuse, multiple unilateral stenoses involving
the CIA, EIA, and CFA (usuaUy>10 ern)
10. Unilateral occlusion involving both the CIA and
EIA
11. Bilateral EIA occlusions
12. Diffuse disease involving the aorta and both
iliac arteries
13. Iliac stenoses in a patient with an abdominal
aortic aneurysm or other lesion requiring aortic
or iliac surgery
Abbreviations: CIA, common iliac artery; EIA,
external iliac artery; CFA, common femoral artery.
Recommendation 32: Treatment of choice for TASC
type A and D aortoiliac lesions
Endovascular procedure is the treatment of choice
for type A lesions, and surgery is the procedure of
choice for type D lesions.
Critical Issue 10: Treatment of TASC type Band C
lesions
More evidence is needed to make any firm recom-
mendations about the best treatment for type Band
C lesions."
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*CIRSE dissenting opinion:
Currentlij endouascular treatment is more connnonuj used
for type B and C lesions, but more evidence is needed to
make mlYfirm reconnneudatioins about best treatment.
Reasoll for disselltil/g opil/ioll: Due to technical develop-
tnenis, type C lesions of iliac and femoral arteries call be
treated by endouascular means toith a resonable technical
success rate (jar references, seeB 4.3).
Therefore, CIRSE believes that ill clinical practice these
lesions are more C0Il111lOlIly treated by eudouascular tech-
niques, altllOllgh scientific evidence ofallY euperioriuj over
oascular sllrgery is lacking.
The technical and initial clinical success of PTA of
iliac stenoses (Figure 21) in all series exceeds 90%
and for focal iliac stenosis approaches 100%. The
technical success rate of recanalisation of segmental
(external or common) iliac occlusions is 80% to 85%
with or without additional fibrinolysis. Only a few
studies have carefully documented clinical results
over a long period of follow-up using standard life-
table methods and more exclusively in claudicants.
These are listed in Tables 17 and 18. Long-term
patency rates in patients with Ie are close to 80% at
1 year and 60% at 5 years (Table 17, Table
18).3,4.5.6.7.8.9.10 Once an iliac artery occlusion has been
•
For details. see recommendation 31 and accompanying text.
Note not ail lesions described in recommendation are illustrated•
Type A
TypeS Currently, endovascular treatment is
more often used but insufficient
evidence for recommendation
TypeC Currently surgical treatment Is
more often used but Insufficient
evidence for recommendation
Type 0 Surgical treatment of choice
Figure 21: Summary of preferred options in interventional management of iliac lesions .
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Table 17: Patency rates for PTA of iliac artery stenoses (patency based on ABPIl
C1aud- Technical
Patients Study icants success Primary patency rate (%)' Cornplic-
(limbs) design (%) (%) ly 3y 5y ation (%)t Comments
Tegtmeyer et aJ,31991 200 (263) R 59 93 92 82 78 4.4 85% 5yr secondary
patency
Jeans et al,' 1990 180 (243) P 73 88 67 60 57 62% 5yr primary
patency in daudicants
Jorgensen et al,5 1992 150 (174) R 71 93 79+ 68+ 63+ 2.3 81% 5yr secondary
patency
Johnston,61993 (584) R 91 99 77 61 54 3.6 68% 3yr CIA patency
51% 3yr EIA patency
Weigllted average (1,264) 77 95 78 66 61 3.6
Abbreviations: R, retrospective; P, prospective.
"Including technical failures.
tlncluding major or 'significant' complications, as far as distinguished in the text.
:j:Adjusted for inclusion of technical failures.
Modified from Bosch JL, Hunink MGM.18
Table 18: Patency rates for PTA of iliac artery occlusions (patency based on ABPIl
C1aud- Technical
Patients Study icants success Primary patency rate (%)' Cornplic-
(limbs) design (%) (%) ly 3y 5y ation (%)t Comments
Colapinto et al,? 1985 (64) R 88 78 68+ 61+ 3.1 I/up by ABPI
Hausegger et '11,8 1991 42 (42) R 81 83 67 5 I/up by ABPI; addi-
tional fibrinolysis in
36 patients; secondary
stcnt placement in
16 patients
[ohnston,s 1993 (82) R 91 82 60 48 4.8 59% 3-year patency
excluding recanalisa-
tion failures; 66% 3-
year success rate after
Cox regression estimate
Blum et al,9 1993 47 (47) P 98 94+ 85:j: 10.6 f/up by Duplex; fib-
rinolysis in all cases;
secondary stents in
18 patients
Gupta et al,lO 1993 50 (56) R 77 79 59+ 56+ 56+ 8.0 f/up by ABPI; 61%
3-year secondary
patency
Weighted Gl'CTage (291) 82 83 68 60 6.0
Study design: R= retrospective. Peprospectlve. f/up=follow-up.
'Including technical failures.
tlncluding major or 'significant' complications, as far as distinguished from the text.
:j: Adjusted for inclusion of technical failures.
recanalised successfully, the patency rate does not
differ from that for patencies after PTA of stenoses.
However, complications are higher after recanalisa-
tion of occlusions (6.0%) than after standard PTA of
stenoses (3.6%). Factors affecting patency have been
identified (see A 3.2.9, Patency, p 537). Better results
can be expected in common versus. external iliac
stenoses, short segmental versus long diffuse
stenoses, patients with good versus poor runoff, and
patients with Ie versus limb salvage patients.
The use of PTA in the aortoiliac segment produces
better results than when used in the femoropopliteal
region. In an analysis of long-term results in the lit-
erature, Rutherford and Durham" produced compos-
ite patency curves for iliac and femoropopliteal PTA.
Femoropopliteal PTA had twice the initial and early
(l-year) failure rate (16% vs 8% and 20% per year vs
10% per year, respectively) but shared the same late
failure rate (3%/y) as iliac PTA. The 5-year patencies
were 52% and 70%, respectively. Becker et aP2 found
a similar 5-year patency rate (72%) in an analysis of
2,697 cases from the literature, noting that this was
79% in claudicants. Patency rates at 3 years are
approximately 80% when performed for stenosis of
Eur J Vase Endovasc Surg Vol 19 Supplement A, June 2000
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Table 19: Stents in iliac arteries-stenoses
Claud- Technical
Patients Study icants success Primary patency rate (%)* Cornplic-
(limbs) design (%) (%) 1y 3y 5y ation (%)t Comments
Palmaz et al,ISJ992 486 (567) P 68 99 91 69 6.4 patency rate based on
clinical stage
Strecker et al,191993 116 (116) R 66 100 95 95 f/up based on ABPI
Wolf et al,2O 1993 37 (56) R 86 100 94 10.8 f/up based on ABPI
Long et al,21 1995 61 (64) P 91 97 84 41 3.3 f/up based on
Duplex
Henry et alp 1995 184 (184) P 93 99 94 86 1.0 f/up by Duplex;
major complications
from both iliac and
fempop stents; 94%
3yr secondary patency
SE3%
Martin et alP 1995 (163) P 77 97 81 4.3
Vorwerk et alp 199628 109 (118) R 97 100 97 86 72 3.4 f/up by Duplex
and/or DSA; 91% 3yr
secondary patency
SE3%
Murphy et al,29 66 (99) 52 91 78 53 7.6
Tetterooet al, 21 1998 143(149) P 100 99 89 0 f/up by Duplex; part
of randornised study
Weighted average 1,365(1,430) 78 99 90 74 72 6.3
Abbreviations: R, retrospective; P, prospective; flup,follow-up.
"Including technical failures.
tincluding major or 'significant' complications, as far as can be distinguished from the text
Modified from Bosch JL, Hunink MGM.18
Table 20: Stents in iliac arterics-occlusions
Claud- Technical
n Study icants success Primary patency rate (%)* Cornplic-
(limbs) design (%) (%) 1y 3y 5y ation (%)t Comments
Hausegger et al,81991 16 (16) P 81 94 94 5 F/up based on ABPI
Blum et all 1993 18 (18) P 64 98 89 78 10.6 F/up based on
Duplex; primary
fibrinolysis
Vorwerk et al,11 1995 127 (127) R 91 80 68:1: 62:1: 35:1: 5.8 F/up based on duplex
or DSA; 69% 3-ycar
secondary patency;
3%SE
Weighted average 187 86 82 72 64 5.6
NOTE. Study design: R, retrospective; P, prospective.
"Including technical failures.
t Including major or 'significant' complications as far as can be distinguished from the text.
:j: Adjusted for inclusion of technical failures
the iliac artery and 60% when performed for occlu-
sion. An approximately 20% difference also is found
between common iliac and external iliac stenoses.
Thus, it is clear that lesion location and morphology
greatly affect PTA results and that the selective appli-
cation of PTA for claudicants should be aimed at
"favourable" lesions. Selective stenting may improve
these results, but the use of stenting to extend PTA to
more extensive (less favourable) lesions has not been
proved to be more efficacious and is more costly (see
also B 4.3, Endovascular Procedures, p S82).IW
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84.3.3
Aortoiliac Stents
The availability of stents for use in aortoiliac PTA
has improved the immediate haemodynamic results
of iliac PTA and effectively managed recoil and PTA-
related flow-limiting dissections (Table 19). Another
application of iliac stenting is for treatment of chron-
ic iliac artery occlusions. PTA alone often fails in
cases of iliac occlusion because of dissection and
marked clastic recoil with re-obstruction of the
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lumen and a residual pressure gradient. Thus, before
1989, the available literature was more critical to the
use of PTA for iliac artery occlusions. This has
changed since large series have demonstrated a 1-
year and 3-years patency rate after successful
recanalisation of 90% and 80%, respectively (Table
20).8.9,15
Thus, the indications for iliac artery stenting, which
are generally accepted in clinical practice, are as fol-
lows:
• Insufficient haemodynamic result of PTA due to
elastic recoil based on residual pressure gradient
• Massive, lumen-obstructing dissection
• Treatment of chronic occlusions
• Iliac artery ulceration associated with symptoms
• Restenoses after previously performed PTA
• Complex lesions for which primary stenting may
give more satisfactory results
The value of haemodynamic measurements in addi-
tion to angiography to assess the result of PTA and
stent placement has been accepted. However, resting
mean and systolic pressure gradients were used as
well as pressure gradients after vasodilatation.
Objective thresholds of pressure gradients for a
haemodynamic significant stenosis do not exist.
However, a resting mean pressure gradient of more
than 5 to 7 mm Hg and a postvasodilatation mean
pressure gradient of more than 10 to 15 mm Hg are
thresholds commonly used to define a haemody-
namically significant lesion» (see Critical Issue 33,
p 5178). However, more recent data have shown
that iliac artery stenting probably provides a more
durable result than PTA alone for both stenoses and
occlusions on an intention-to-treat basis. One obvi-
ous reason is that stenting provides a better early
result, which raises the starting point of the life-
table curve.F
Critical Issue 11: Use of pressure gradients to assess
haemodynamic significance of stenoses
Pressure gradient criteria with or without vasodila-
tors for assessing haemodynamic significance in
iliac lesions remain to be established.
Critical Issue 12: Multiple stents
The usefulness and cost-effectiveness of multiple
stents have yet to be established.
A recent meta-analysis by Bosch and Hunink'" com-
paring the results of aortoiliac PTA versus. aortoiliac
stenting used a Medlars search of the post-1989 litera-
ture and yielded only six articles (including 2,116
patients) with sufficient detail to allow stratification
over subgroups with various risk levels for long-term
patency. Technical success was higher for stenting,
whereas complication rates and 3D-day mortality rates
did not differ significantly. In patients with intermit-
tent claudication, the severity-adjusted 4-year primary
patency rates (±95% confidence intervals) after
excluding technical failures, for PTA and stenting,
were: 68% (65%-71%) and 77% (72%-81%), respective-
ly. Including technical failures, the 4-year primary
patency rates are 65% (PTA) versus 77% (stent) for
stenosis and 54% (PTA) versus 61% (stent) for occlu-
sion. The relative risk of long-term failure was
reduced by 39% after stent placement compared with
PTA.
In a re-analysis of the Palmaz multicentre iliac data,
Laborde et al-? determined the influence of anatomic
distribution of atherosclerosis (ie, disease severity) on
the outcome of revascularisation by stenting. They
divided the 455 patients of the study population into
three groups according to the Brewster classification
of disease patternsv and then used a statistical analy-
sis to determine differences in outcome between
groups. Brewster pattern type I includes only those
patients with focal aortoiliac disease or common iliac
disease (39.6% of the study group); Brewster pattern
type II includes external iliac artery lesions (12.8% of
the study group); Brewster pattern type III or multi-
level disease involving the infrainguinal vessels was
seen in 47.7% of study patients. "Complete relief of
symptoms" occurred in 88.3% and 85.4% of Brewster
pattern type I and II patients, respectively, whereas
only 60.1% of those with Brewster pattern type III
experienced complete relief (p < 0.05). Persistent clini-
cal benefit at 36 months was seen in 91.6% and 97.9%
of patients with Brewster pattern type I and type II
disease, respectively, as compared with 60.8% in type
III (p =0.006 for type II vs type III and p = 0.001 for
type I vs type III, Wilcoxon test). Multivariate logistic
regression showed that pattern type III was the most
powerful indicator of unsatisfactory early outcome in
iliac stenting (p < 0.001). Female gender also predicted
unsatisfactory clinical outcome (p < 0.01) and higher
periprocedural complications (p < 0.001).
The Dutch Iliac Stent Trial compared primary stent
placement versus primary angioplasty followed by
selective stent placement in patients with claudication
caused by iliac-artery obstructive disease.F In the PTA
group, selective stentplacement was performed in 59
of 136 (43%) with a residual mean pressure gradient
greater than 10 mm Hg after balloon angioplasty. A
primary technical success was achieved in 279 of 286
patients (97.5%). A haemodynamic success was
achieved in 97% of the successfully recanalised iliac
arteries. At 2 years, the clinical success rates were 78%
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versus 76%, the haemodynamic success rates as
assessed by ABPI measurements were 85% versus
85%, and the patency rates as measured by colour
Duplex were 71% versus 70% in the stent versus PTA
plus stent groups, respectively.
It should, however, be remembered that most
patients in this study had IC with mild lesions, and the
results cannot be extrapolated to patients with more
severe lesions. Thus, selective stenting yields equiva-
lent effectiveness and is less costly than primary stent-
ing in the treatment of claudication due to iliac artery
stenoses.ts-" Furthermore, selective stenting compared
with PTA alone yields an increase in effectiveness that
justifies the additional costs in these cases. (see Table
19).22,23,24,25,26,27,28,29
To summarise, stents have influenced modern aor-
toiliac PTA by providing a means to oppose elastic
recoil, treat PTA-related dissections, and improve the
long-term clinical results. In addition to these benefits,
stents have provided a method to effectively treat
TASC types C and D aortoiliac bifurcation disease in
selected patients. The short- and long-term clinical
benefits of iliac stenting are influenced by anatomic
distribution of disease. Benefit is less variable and
complications and mortality are higher in patients
with Brewster type III diseases than in those with
Brewster types I and II.
Recommendation 33: Role of stenting for residual
pressure gradient. dissection, or elastic recoil
Stenting improves the technical and initial clinical
success in cases of residual pressure gradient or dis-
section after angioplasty, or in cases of elastic recoil.
Critical Issue 13: Role of primary stenting of iliac
occlusions
Primary stenting is widely used to optimise proce-
dural results in iliac artery occlusions. This practice
needs to be subjected to rigorous clinical evalua-
tion.
84.3.4
Femoropopliteal PTA
Selected PAD patients with claudication may be con-
sidered for femoropopliteal PTA. There are, however,
additional considerations. Patients with isolated aorto-
iliac disease tend to be younger and have a low likeli-
hood of coronary heart disease comorbidity, whereas
those with femoropopliteal disease, infragenicular dis-
ease, or multilevel disease tend to have the lowest
ABPI and the highest likelihood of coronary heart dis-
ease comorbidity.3o,31,32,33,34,35,36 Preservation of the
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Recommendation 34: Morphological stratification
of femoropopliteal lesions
TASC type A iliac lesions:
1. Single stenosis <3 em of the CIA or EIA [unilat-
erallbilateral)
TASC type B iliac lesions:
2. Single stenosis 3-10 ern in length, not involving
the distal popliteal artery*
3. Heavily calcified stenoses up to 3 cm in length
4. Multiple lesions, each less than 3 cm (stenoses
or occlusions)
5. Single or multiple lesions in the absence of con-
tinuous tibial runoff to improve inflow for dis-
tal surgical bypass
TASC type C femoropopliteallesions:
6. Single stenosis or occlusion longer than 5 cm*
7. Multiple stenoses or occlusions, each 3-5 cm,
with or without heavy calcification
TASC type D fernoropopliteal lesions:
8. Complete common femoral artery or superficial
femoral artery occlusions or complete popliteal
and proximal trifurcation occlusions.
'CIRSE agrees except for tilefollowillg changes:
TypeB[emoropoplitcal lesions:
2, Singlestenosis or occlusions 3-10 em long,1I0t iniolooing the distal
popliteal artery
TypeC[entoropopllteal lcsions:
6. Sillglestenosis or oclusion >10 C/II long
Rcasoll far dissC1ltill~ o1'illioll: The lowerlong-term clinical success rate
of longstenoses and occlusions ill earlier studieswasdue to a low tech-
nicalrate. HOWC1.'CT, developments of catheters and wireshare improved
tile technical success rate, to befollowed by higherpatencv rates.v»
Studiescomparing PTA with bypass surgeryill[emoropoplitcal lesions
4-10 em longdo 1I0t exist.
Recommendation 35: Treatment of choice for TASC
type A and D femoropopliteallesions
Endovascular procedure is the treatment of choice
for type A lesions, and surgery is the procedure of
choice for type D lesions.
Critical Issue 14: Treatment of TASC type Band C
femoropopliteallesions
More evidence is needed to make and firm recom-
mendations about the best treatment for types B
and C lesions.
saphenous veins for coronary bypass grafting is a
potential advantage in such patients, in whom the
benefit/risk ratios of surgery, PTA, and conservative
therapy must be weighed, Some high-risk patients
may be offered PTA for their claudication; however,
for such patients, for example, those with diabetes
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mellitu s, surgical bypass is usually reserved for severe
leg ischa emia. As w ith aortoiliac di sease,
femoropopliteallesions ha ve been categorised in mor-
phological terms, with preferred therapeutic options
as follows:
Several important studies of femoropopliteal PTA
hav e appeared in the lit erature in recent years
(Figure 22).4;37,38,39,40The primary success rates and the
long-term patency rates of the successfully dilated
arteries are listed in Table 21. In only one study were
all pati ents claudicants. Table 22 shows estimated
patency by length of lesion. These results are also di s-
cussed in Critical Limb Isch aemia (D 4.9,
Infrainguinal Disease-Endovascular Treatment, p
5192).
Factors predicting outcome of PTA were evaluated in
three studies37,38;39 using a Cox stepwise multiple regres-
sion model. Factors predictive for a favourable outcome
are claudication as an indication, nondiabetic patients,
proximally located short lesions, stenoses, good distal
run-off, and lack of a residu al stenosis on the post-PTA
angiogram. However, it also has been claimed that once
an occlusion has been recanalised, the long-term paten-
cy does not differ in comparison with stenoses." The
technical success rate in stenoses is greater than 90%; in
occlusions, 80% to 85%.
The studies listed in Table 21 illustrate several inter-
esting findings on the issue of transluminal treatment
of stenoses versus occlusions. Studies approximately
15 years old, such as those of Gallino et apt and Krepel
et al,42 tended to show a greater impact of occlusion
length on initial technical success rates (33% and 26%,
respectively, for occlusions larger than 3 em) com-
pared wit h more recent studies. For example, in
Matsi's 1994 study, the technical success for occlusi ons
2 to 15cm in length wa s 83%. This compared to 91%
for 125 stenoses." In Murray et al's40study, the authors
remarked that earlier results of angioplasty bore little
relevance to the results that could now be achieved.
Once a lesion is crossed and dilated, it has the same
anticipated long-term success as a stenosis treated by
PTA.37Therefore, the principal reason that clinical suc-
cess rates reported in the past were lower for PTA of
femoropop liteal occlusions than for stenoses is that
with lower initial technical successes the curves for
occlusion started off lower, The life-table patency and
cumulative clinical success curves are, in fact, essen-
tially parallel.
Table 21: PTA of femoropopliteal a rter ies-sten oses and occlusions
Claud- Technical
Patients Study ican ts success Pri mary pat ency rate ('Yo)' Complic-
(limbs) design ('Yo) ('Yo) l y 3y 5y ati on ('Yo)t Com ments
Gallino et aI," 198-t 280 (329) R 61 87 62~ 60~ 58t 2.5 Flup based on
ABPI; 7-1 % 2-y
primary pa tency in
stenoses, <3 em
occlusions in claudican ts
Krepel et a\,'2 1985 129 (16-1) R 90 8-t 68~ 57t 57:j: 6.0 38 by coaxial Dotter
se t; 88% technical
success in 126 balloon
cases
Jeans et a\,' 1990 190 (190) P 51 82 50 -15 -11 Flup based on ABPI;
5-y pa lencies- 61%
(stenoses) 31%
(occlusions)
Capek et al, 37 1991 152 (217) R 7-1 90 71t 51:j: -I8:j: 5.5 Fl up based on ABPI
Johnslon,38 1992 236 (25-1) R 80 96 63 51 38 6.3 Fl up based on ABPI;
stenoseslocclusions
£JOcm
Hunink et al,n 1993 106(131) P 58 95 57 -15 -15 2.-1 Fl up based on ABP/;
55% 5-y patency for
stenoses+occlusions
Matsi et all ' 199-1 106 (1-10) P 100 89 -17 -12 -1.0 Flup based on ABPI;
59% 3-y secondary
patency
Murray et .11,'" 1995 -12 (+t) P 89 93 86 53 5.0 Fl up based on duplex;
> lO-Cm lesions only;
2-1-mo pa tency, SE 26%
Weigh/cdal'Crage 1,241 (1,469) 72 90 61 51 48 4.3
Abbreviations : R, retrospective, I~ prospecti ve.
'Includ ing technical failures .
tlncluding major or "significan t" complications, as far as can be di st inguish ed from the text.
:j:Adjusted fo r inclusion of tech nical fail ures.
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For details see recommendation 33 and accompanying text
Note not all lesions described In recommendation are illustrated
Type A Endovascular
treatment of choice
J-<3cm-i
Type B Currently, endovascular ~
treatment is more oftenused/ ~
but insufficient evidence to
make recommendation I 3-5cm I
Not
distal popliteal
TypeC Currently, surgical
treatment is more often
used, but insufficient
evidence to make
recommendation
~
/
/' a-scm
"'~I- <3·5cm-i I- <3-5cm-i
Type 0 Surgic.al treatment
of cholce
-:FIlA:
>5cm---~
Fig. 22. Summary of preferred options for interventional treatment of femoropopliteal lesions.
[ohnston's" report seems to show dramatically
better results for PTA of femoropopliteal stenoses
than occlusions. However, this was a re-analysis of
an old PTA series and was therefore subject to the
same problems and limitations mentioned previous-
ly for older PTA series. The most important factor
that emerged from Johnston's study, as well as oth-
ers , is that patients with poor (0- to I-vessel) runoff
consistently show poorer long-term outcomes than
those with 2-3-vessel runoff. 38.39AOA " ~2 A summary of
these observations is that (1) older femoropopliteal
PTA studies describe lower technical success with
femoropopliteal occlusion than do newer studies; (2)
because of arbitrary limits placed on the translumi-
Eur JVase Endovasc Surg Vol19 Supplement A, June 2000
nal technique and imposed on a generation of inter-
ventionists, long-segment occlusions have not com-
monly been attempted; (3) in the older literature, the
apparently lower long-term clinical success of PTA
for femoropopliteal occlusions compared with
stenoses was attributable in large part to lower tech-
nical success (lesion crossing) and a resultant lower
starting point on an otherwise identical life-table
curve (lower, but parallel); (4) by far the most consis-
tent, important determinant of long-term clinical
success versus failure among the studies listed in
Table 21 is not occlusion versus stenosis at all, but
rather the status of the runoff circulation below the
knee.
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Table 22: Estimated patency by length of les ion
891
Referen ce Length of lesion Patency (%) Inclusion of technical failures Ind ication
Jeans et aV 1990
Krep el et al,33 1985
Krep cl et al JS 1985
Gallino ct al,37 1984
Currie et aV~ 1994
Murray et al,36 1995
<1 cm
<2cm
<3cm
<3cm
<5cm
<7cm
Stenoses @5 y;
<1 ern = 76
>1 ern = 50; p < 0.05
longest lesion length implied
> 5 cm primary patency
stenoses @5y;
<2cm = 77
>2 em = 54
longest lesion length not
stated primary vs secondary
patency not stated
occlusions @1 y;
<3 cm =93
>3cm = 50
longest lesion length not
stated primary vs secondary
patency not stated
@2 y; stenoses/occlusions
< 3 cm with 2-3 vessel run-
off = 71 occlusions with 0-1
vessel run-off = 37
~6 mo;
<5cm=59
>5 em =4
stenoses @6 mo ;
<7cm = 81
>7cm=23
longest lesion length not stated,
implied> 10 ern.
Secondary patency but <5%
redilated
technical failu res
included in life table
technical failures
excluded from results
technical failures
excluded from results
primary patency
technical failures
excluded from results
immediate failures
excluded
CLl with ABPI <0.5
90% claudication
90% claudication
claudication + CLl
CLl predominant
claudication 66%
rest pa in 34%
Table 23: Outcome of PTA and bypass of femoropopliteal obstructions---elaudication (modified from Hunink et alii)
Indication
PTA-stenosis
PTA-occlusion
Femoropopliteal bypass-vein
Femoropopliteal bypass-PTFE AK
Femoropopliteal bypass-I'TFE BK
An important study in this area is a decision and
cost-effectiveness analysis of revascularisation proce-
dures for fernoropoplitcal disease by Hunink et al
(Table 23; Figure 23).45The authors used a literature
review of mortality, morbidity, patency, and cost data
as a source. They included only procedures per-
formed after 1985. There were 4,800 PTA and 4,511
bypass operations. They developed a decision ana-
lytic model to examine the choice between bypass
surgery and PTA for lesions amenable to either pro-
cedure. These patencies were offered to guide initial
strategy in patients with disabling claudication and
femoropoplitcal lesions.
Patency modelled on 5 years (%)
68
35
80
75
65
84.3.5
Femoropopliteal Stents
The most troublesome lesions for femoropopliteal
PTA include eccentric stenoses, long-segment stenoses
and occlusions, and stenoses due to intimal hyperpla-
sia at graft anastomoses. Balloon dilatation of these
Recommendation 36: Femoropopliteal stenting in
PAD
Femoropopliteal stenting as a primary approach to
the interventional treatment of intermittent claudi-
cation or eLI is not indicated. However, stents may
have a limited role in salvage of acute PTA failures
or complications.
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•
•
Pooled weighted data from tables 16 to 22
Predominately in claudication
Primary pate ncy, incl uding tec hnical fa il ur es, at 1, 3, and 5
Tochn ical Failures%
Complications % ~
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Fig. 23. Average results for endovascular treatment.
lesions can fail because of elastic recoil. It also may fail
because of obstructing intimal flaps caused by exten-
sive dissection. Stents have been applied as a potential
solution. In general, the immediate and early results
have been excellent, and many cases of angioplasty
failure have been converted to early successes because
of the impact of stents. However, restenosis caused by
intimal hyperplasia in the stented segment is quite
common in the first 3 to 9 months after treatment.
Preliminary studies us ing a variety of stents show less
than promising results because of intimal hyperplasia
and occlusion (Table 24).26.27.46AS.49.50.51 There is some ref-
erence to an increased risk of compression of balloon-
expandable stents in femoropopliteal arteries. This
may be caused by external trauma or muscle com-
pression within the adductors canal. Therefore, the
use of self expandable stents seems advisnble.v
In general, it may be stated that the experience
with infrainguinal stenting for femoropopliteal dis-
ease has been limited. Stents appear indicated only
for salvage of failed PTA attributable to dissection or
marked recoil. Finally, covered stents may have a
role in limiting or preventing restenosis caused by
intimal hyperplasia. This concept is in trials now, but
has not yet been proved.
Cejna et al 56 performed a multicentre, ran-
domised trial. PTA was compared with Palmaz
stent implantation in femoropopliteal artery
obstructions in 142 patients (154 lesions). In 10 of
77 patients randomised to balloon angioplasty, pri-
mary PTA failed (12.9%) as compared with one pri-
mary stent failure (1.3%) . Cumulative primary
angiographic patency rates for PTA were 79%, 64%,
and 53% at 6, 12, and 24 months, respectively.
Primary patency rates for stent placement were
86%,63%, and 58% at 6, 12, and 24 months, respec-
tively. Thus, despite better short-term and
midterm results, primary stenting does not
improve long-term success rates as compared with
PTA alone. Table 25 summarises the weighted-
average primary patency rates for iliac and
femoropopliteal procedures.
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Table 24: Stents in femoropopliteal arteries-stenoses and occlusions
Claud- Technical
Patients Study icants success Primary patency rate (%)' Compllc-
(limbs) design (%) (%) ly 3y 5y ation (%)t Comments
Rousseau et al,-l6 1989 36 (40) P 78 100 76 0 I/up based on DSA;
25% lesions >7 ern
length; 30% total
occlusions
ZoIIikofer et al,~7 1991 13 (15) P 76 93 55 18 6.6 f/up based on ABPl
and angiography;
80% occlusions with
average length 135 an
Do et al,~ 1992 26 (26) P 85 100 59 ffup based onABPI
and duplex; 100%
occlusions; 69% sec-
ondary patency at 1 y
Sapoval et al;o 1992 21 (22) P 86 95 49 49 4.5 flup based on
duplex and angiogra-
phy; 82% occlusions;
67% secondary
patency at 1 y
Liermann et aI,S<) 1992 48 (48) R 65 94 71 4 flup based on ABPI
Henry et al,26 1995 126(126) P 93 99 81 72 65 1 Ffup based on duplex;
major complications
from both iliac and
femoropopliteal
arteries; 31% occlu-
sions; 96% secondary
patency at 1 y, 1.8% SE
Martin et alP 1995 96 (96) P 77 61 17 ffup based on ABP1;
84% secondary
patency at 1 y
White et al,53 1995 32(32) P 94 100 75 Ffup based on
Doppler; 47% occlu-
sions; 93% secondary
patency at 1 y
Bray et al,51 1995 (57) P NA 100 79 I/up based on
Dupl ex; 61% occlu-
sions; 82% secondary
.patency at 1 y
Strecker et aJ,51 1997 80 (80) P 82 98 76 48 8.8 ffup based on ABP1;
59% occlusions
Gray & Olin,55 1997 50(58) P 50 100 22 12.0 f/up based on
Duplex ; 89% occlu-
sions with av, length
16.5an; 46%secondary
patency at 1 y
Weightcd al'i.'rage 585(600) 80 98 67 58 7.3
Abbreviations: R, retrospective: P, prospective; flup, follow-up.
'Including technical failures .
tlncluding major or "significant" complications, as far as can be distinguished from the text.
Table 25: Weighted-average primary patency rate in patients with intermillent claudication, including technical failures.
Patency rates excluding technical failures are shown in parentheses.
Technical Primary patency rate (%)
success (%) ly 3y 5y
PTA iliac stenoses 95 78 (83) 66 (71) 61 (66)
PTA iliac occlusions 83 68 (85) 60 (77)
Stents iliac stenoses 99 90 (91) 74 (75) 72 (73)
Sten ts iliac occlusions 82 75 (90) 64 (82)
PTA femoropopliteal 90 61 (71) 51 (61) 48 (58)
Stents femoropopliteal 98 67 (69)
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Infrapopliteal PTA
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84.3.7
Complications of Endovascular Procedures
Unlike the aortoiliac and femoropopliteal segments, the
infrapopliteal vessels are usually not treated unless
there is critical acute or chronic limb ischaemia.
Therefore, most of the experience in infrapopliteal
endovascular recanalisation has come from patients
with limb-threatening ischaemia. However, more
recent reports of PTA of tibial arteries have also includ-
ed patients with severe claudication.57,58,59,60 The pri-
mary goal of infrapopliteal PTA in patients with IC is
improvement of the outflow after femoropopliteal PTA,
stent placement, or bypass. The rationale for this is the
fact that the distal runoff has a significant influence on
the long-term patency rates after femoropopliteal PTA
and bypass surgery.37,38,6! Dotter and Judkins! and oth-
ers first described infrapopliteal PTA; however, results
were mixed.!,62,63 The efficacy of infrapopliteal PTA has
been substantially improved by technical develop-
ments, _such as D5A with road mapping, steerable
guidewires, and low-profile balloons. Indications for
treatment are categorised by symptomatology, anatom-
ic localisation, and clinical outcome (see also C 4.2,
Endovascular Procedures for Acute Limb Ischaemia, p
5129; D 4.6, Aortoiliac Disease-Endovascular
Treatment, p 5182;D 4.9.2,Infrapopliteal Angioplasty, p
5193). In summary, experience is accumulating that
demonstrates the effectiveness and safety of
infrapopliteal artery PTA. However, it is still debatable
whether infrapopliteal PTA should be performed in
patients with IC for improvement of outflow and for an
increased patency of proximal dilatation sites.
Critical Issue 15: Infrapopliteal percutaneous
transluminal angioplasty in intermittent claudica-
tion
The role of infrapopliteal percutaneous translumi-
nal angioplasty to improve run-off in intermittent
claudication remains to be established.
Complications of percutaneous treatments of PAD
include the risks of the diagnostic study with the
increased risks of all the therapeutic modalities
employed: lysis, PTA, stents. Interventional morbidity
increases because of larger vascular access that often is
needed for treatment and the use of anticoagulation,
and also because of the additional catheter-guidewire
manipulations needed for therapy. Published compli-
cation rates vary considerably. As with efficacy, report-
ing of complications is not standardised. Some series
have included complications with no clinical sequelae
or have classified technical failure as a complication.s-
Many older reports included as complications events
that currently could be managed by either percuta-
neous techniques applied during the ongoing proce-
dure (eg, lysis for distal embolic events) or noninva-
sive maneuvers (eg, ultrasound-guided compression
for femoral pseudoaneurysms). Furthermore, it is dif-
ficult to derive a single value for complication rates in
claudicants or CLI patients alone, because most
reported series comprise both claudicators and limb
salvage patients.
Complications can be classified as major (resulting
in unplanned increase in the level of care, prolonged
hospitalisation, permanent adverse sequelae or death)
or as minor. Becker et al65 reviewed complications of
4,662 published PTA procedures. Major complications
were observed in 5.6%. In 2.5%, surgery was required;
limb loss was observed in 0.2%, and another 0.2%
died. Minor complications were observed in 4.6%. In a
prospective series accumulated after the period cov-
ered by Becker's review, Matsi and Manninen's noted
a similar complication rate of 10.5%, with 2% requir-
ing operative repair. As with Becker et al, these
authors noted that major complications constitute
approximately half of the total (major plus minor)
complications. When percutaneous or interventional
Table 26: Summary of aggregate complication rates for endovascular procedures
Source
Table 17
Table 18
Bosch & Hunink,» 1997
Bosch & Hunink," 1997
Table 21
Table 24
Aorloiliac intertcntions;
PTA of a stenosis
PTA of an occlusion
PTA all lesions
Stents all lesions
Fetuoropopliteal interocntions;
PTA
Stents
Weighted awrage complication rate (range)
3.6% (2.3-l.4%)
6% (3.1-10.6%)
4.3%
5.2%
4.3% (2.4-6.3%)
7.3% (0-17%)
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therapy is applied to treat complications associated
with PTA, it can be expected to be successful in 75% of
patients.w The most common complications are
thromboembolic vessel occlusions and puncture site
injury such as a haematoma or false aneurysm. Less
commonly, complications occur at the PTA site itself,
including thrombosis, dissection, perforation, and
occlusion. Endovascular Procedures (B 4.3, S82) and
Section 0 4.12.5, Incidence and Management of
Complications, give aggregate complication rates for
specific procedures, which are also summarised in
Table 26.
Gardiner et al67reviewed the complications of PTA
and reported a rate of major complications of 3% for
iliac PTA and 3% for femoropopliteal PTA. Hence,
there may be no difference in complication rate
between iliac and femoropopliteal PTA. In studies of
stent placement, higher complication rates were
reported, which might be explained by the learning
curve of the investigators. Martin et aJ27 noted that
femoropopliteal stent placement engendered higher
complication rates than iliac stent placement because
of bleeding related to the antegrade approach; the
more frequent use of anticoagulation during and after
stent placement in the infrainguinal vessels (when
compared with the iliac arteries) is probably another
factor. Recanalisation of iliac artery occlusions has an
increased level of complications (mostly thromboem-
bolic events) of 6% to 16%,6,7,8,9,15,26 especially when the
occlusions are longer than 2 cm.66
Complex lesions associated with long procedure
times and multiple catheter manipulations and
exchanges probably predispose to higher complication
rates. Patient factors such as obesity can increase punc-
ture site complications. Cardiac and renal comorbidi-
ties frequently found in this group also contribute to
increased risk. The 30-day mortality rate of patients
undergoing PTA was 4% in one recent study; the clau-
dicators in this group had a 0.5% 30-day mortality rate,
whereas the limb salvage patients endured a 10%30-
day mortality rate. 66 Thus, the complexity of limb sal-
vage patients apparently places them at higher risk
than the aggregate population of treated patients as a
whole, but this must be weighed against higher poten-
tial surgical morbidity. Management strategies specific
for PTA and stent placement that may reduce the inci-
dence of potential complications include the use of
low-profile devices as well as use of the contralateral
approach in obese patients or in easily accessible
lesions.e Familiarity with ultrasound compression for
puncture-site pseudoaneurysms, lysis for distal
embolisation, and stent placement for occluding dis-
sections will all increase effectiveness and decrease
morbidity from these procedures.
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Surgery for Intermittent Claudication
B 4.4.1
Introduction
The most compelling indication for an open surgical
revascularisation procedure on the lower limb is
critical limb ischaemia (rest pain, tissue loss).
Therefore, surgical procedures are discussed in
greater breadth and depth in the section of the doc-
ument dealing with CLI (Section 04, Treatment of
Critical Limb Ischaemia, p 5163). The following sec-
tion addresses only the limited application of surgi-
cal procedures appropriate to the treatment of
patients with K'.
Surgery is rarely necessary in patients with IC; in
fact, surgery should be avoided initially and other
options pursued in most patients. The generalised
disease process present in patients with atheroscle-
rotic occlusive disease is not benefited by limb revas-
cularisation, other than the relatively minor consid-
erations that increasing exercise capacity may
improve conditioning and allow exercise therapy for
angina. The overriding consideration is that, in the
claudicant, the threat to life of generalised athero-
sclerosis takes priority over the limited threat to
limb of the peripheral lesions. In a non-limb-threat-
ening situation, conservative treatment will provide
sufficient improvement in most, so the risk of both
early and late complications associated with bypass
grafting cannot be justified. However, exceptional
circumstances do exist, and these deserve discus-
sion, for in practice, valid exceptions to the general
reservation against surgical revascularisation may
occur.
Ordinarily, if exercise therapy fails or is rejected
by the patient for other reasons, these patients may
try pharmacotherapy or be referred for imaging to
evaluate the possibility of balloon angioplasty. If
these options are not possible, or fail, surgery may
be considered. The decision to involves an individu-
alised risk:benefit analysis, balancing the benefit of
relieving that particular patient's disability against
the immediate risks (morbidity/mortality/technical
failure) and the risk of late failure of the proposed
surgical procedure. This weighing of risk and bene-
fit must be settled in the patient's favour.
B 4.4.2
Surgical Procedures
General considerations
Surgical procedures arc discussed separately in terms of
the results of their application to proximal or distal
disease, the common femoral artery being the bound-
ary. This is because not only is the patency durability
better for proximal disease but one often can treat both
legs with the same procedure. Even if a single-leg
bypass does not fail, claudication may return because
of progression of like lesions in the contralateral
extremity. The latter is not gauged by standard out-
come measures.
Continuing this comparison, distal procedures usu-
ally can be performed with a lower general and sys-
temic, but not local, morbidity rate than proximal pro-
cedures performed through abdominal incisions. The
use of prophylactic antibiotics has reduced the risk of
graft infections to a rare but disastrous occurrence,
whose risk is increased if there is a groin incision.'
Finally, although the overall cardiac mortality/mor-
bidity risk would seem intrinsically greater for those
proximal reconstructions involving aortic exposure
and clamping, this is balanced by the fact that those
with distal disease, specifically diabetic patients, gen-
erally have a higher prevalence of atherosclerotic
involvement of cardiac, renal, and other visceral circu-
lations. Their perioperative risk is as high and their
survival worse than proximal reconstructions.s>
Although these overall observations do not apply
specifically to patients with IC, a peripheral/distal
procedure cannot be assumed to be inherently less
risky than a proximal one and thus easier to justify in
a claudicant.
The patency rate for operations to treat inflow dis-
ease (aortoiliac occlusive disease) is also better than
that of fernoropopliteal bypass. There are few direct
comparative data in equivalent cases indicating which
type of bypass graft (extraanatomic ys anatomic, uni-
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